Aprea Therapeutics Inc (APRE)

$0.77 -0.02 (-1.93%)
Market Cap 9.94M
Revenue (ttm) 290,000.00
Net Income (ttm) -12.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,344.83%
Debt to Equity Ratio 0.00
Volume 127,700
Avg Vol 261,444
Day's Range N/A - N/A
Shares Out 12.59M
Stochastic %K 7%
Beta 1.54
Analysts Strong Sell
Price Target $3.73

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid t...

Industry: Biotechnology
Sector: Healthcare
Phone: 215 948 4119
Website: aprea.com
Address:
3805 Old Easton Road, Doylestown, United States
Netonay
Netonay Sep. 10 at 5:34 PM
$APRE Some day I’m going to wake up and this shit is going to be 25 plus ,,, then people will chase! Mark this post !
0 · Reply
MavrickPete
MavrickPete Sep. 8 at 1:31 AM
$APRE $41.3M cash as of June 2026, with runway into Q1 2028..!!
0 · Reply
Tradingistheway
Tradingistheway Sep. 7 at 4:49 AM
$APRE https://www.instagram.com/reel/DcbM1l5iJBX/?stkn=MTBsNXkycDVmMmY2aw==
0 · Reply
focafoca99
focafoca99 Aug. 28 at 12:30 PM
$APRE expanded its patent portfolio for precision oncology programs, adding new WEE1 and ATR filings.
0 · Reply
Olyaboo
Olyaboo Aug. 27 at 2:30 PM
$APRE Im holding
0 · Reply
Arttard
Arttard Aug. 27 at 2:25 PM
$APRE why Down Today?
0 · Reply
CoachHendo
CoachHendo Aug. 27 at 8:18 AM
$APRE $NVTS $GNPX Lotto Plays!
0 · Reply
Dcvcool
Dcvcool Aug. 27 at 2:16 AM
$APRE wow not the greatest management and no real trial results yet A real lotto ticket I don’t play the lottery though
0 · Reply
Heroforest
Heroforest Aug. 26 at 5:13 PM
$APRE new here anyone what’s the near term catalyst? In q4 2026 and 2027? Thanks
1 · Reply
PennySearch
PennySearch Aug. 26 at 3:33 PM
📈 Top Penny Stock Movers by Relative Volume $APRE — 6.73x RVOL Move: +10% Volume: 1.8M (274.7K average) Market Cap: $13.2M Day Range: 0.96 – 1.16 52-Week Range: 0.55 – 1.69 $XPON — 5.79x RVOL Move: +69% Volume: 27.6M (4.8M average) Market Cap: $8.5M Day Range: 6.30 – 11.79 52-Week Range: 2.77 – 24.60 $DAIC — 3.26x RVOL Move: +31% Volume: 33.7M (10.3M average) Market Cap: $6.2M Day Range: 4.61 – 6.69 52-Week Range: 0.37 – 111.97 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.
0 · Reply
Latest News on APRE
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026, 8:00 AM EDT - 3 days ago

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Aprea Therapeutics provides update on existing patent portfolio

2026-08-28T12:20:16.000Z - 16 days ago

Aprea Therapeutics provides update on existing patent portfolio

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Aug 28, 2026, 8:15 AM EDT - 16 days ago

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Aprea Therapeutics reports Q2 EPS (7c), consensus (22c)

2026-08-17T09:34:01.000Z - 27 days ago

Aprea Therapeutics reports Q2 EPS (7c), consensus (22c)

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Aprea Therapeutics Earnings release: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

Aprea Therapeutics Earnings release: Q2 2026

Aprea Therapeutics Quarterly report: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

Aprea Therapeutics Quarterly report: Q2 2026

Aprea Therapeutics Slides: Corporate presentation

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Aprea Therapeutics Slides: Corporate presentation

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Jul 30, 2026, 8:00 AM EDT - 6 weeks ago

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics Transcript: AGM 2026

Jun 16, 2026, 9:00 AM EDT - 2 months ago

Aprea Therapeutics Transcript: AGM 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics price target lowered to $6 from $7 at Wedbush

2026-05-14T17:12:08.000Z - 4 months ago

Aprea Therapeutics price target lowered to $6 from $7 at Wedbush

Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year

2026-05-13T11:47:31.000Z - 4 months ago

Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year

Aprea Therapeutics Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Aprea Therapeutics Earnings release: Q1 2026

Aprea Therapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Aprea Therapeutics Quarterly report: Q1 2026

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 13, 2026, 6:30 AM EDT - 4 months ago

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics initiated with an Outperform at Oppenheimer

2026-05-07T11:31:05.000Z - 4 months ago

Aprea Therapeutics initiated with an Outperform at Oppenheimer

Aprea Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Aprea Therapeutics Proxy statement: Proxy filing

Aprea Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Aprea Therapeutics Proxy statement: Proxy filing

Aprea Therapeutics files to sell 74.35M shares of common stock for holders

2026-04-22T21:06:33.000Z - 4 months ago

Aprea Therapeutics files to sell 74.35M shares of common stock for holders

Aprea Therapeutics Registration statement: Registration filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Aprea Therapeutics Registration statement: Registration filing

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Apr 21, 2026, 10:15 AM EDT - 4 months ago

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Aprea Therapeutics Proxy statement: Proxy filing

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Apr 1, 2026, 8:30 AM EDT - 5 months ago

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright

2026-03-31T10:18:45.000Z - 5 months ago

Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright

Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial

2026-03-30T12:44:02.000Z - 5 months ago

Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Mar 30, 2026, 8:01 AM EDT - 5 months ago

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Aprea Therapeutics Registration statement: Registration Filing

Mar 17, 2026, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Registration statement: Registration Filing

Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year

2026-03-16T12:06:55.000Z - 6 months ago

Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year

Aprea Therapeutics sees cash runway into 1Q27

2026-03-16T12:05:48.000Z - 6 months ago

Aprea Therapeutics sees cash runway into 1Q27

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Aprea Therapeutics Annual report: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Annual report: Q4 2025

Aprea Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Earnings release: Q4 2025

Aprea Therapeutics Slides: Corporate presentation

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Slides: Corporate presentation

Aprea Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 8:40 AM EST - 6 months ago

Aprea Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aprea Therapeutics Registration statement: Registration Filing

Feb 20, 2026, 7:00 AM EST - 6 months ago

Aprea Therapeutics Registration statement: Registration Filing

Aprea Therapeutics files to sell 12.58M shares of common stock for holders

2026-02-20T11:11:20.000Z - 6 months ago

Aprea Therapeutics files to sell 12.58M shares of common stock for holders

Aprea Therapeutics announces additional clinical activity for APR-1051

2026-02-18T13:17:13.000Z - 6 months ago

Aprea Therapeutics announces additional clinical activity for APR-1051

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Feb 18, 2026, 8:00 AM EST - 6 months ago

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 6 months ago

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aprea announces expansions of its global intellectual property estate

2026-02-12T13:43:38.000Z - 7 months ago

Aprea announces expansions of its global intellectual property estate

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Feb 12, 2026, 8:30 AM EST - 7 months ago

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Aprea Therapeutics price target lowered to $7 from $11 at Wedbush

2026-02-10T13:20:30.000Z - 7 months ago

Aprea Therapeutics price target lowered to $7 from $11 at Wedbush

Aprea Therapeutics appoints Kennedy as Chief Medical Advisor

2026-02-04T13:35:12.000Z - 7 months ago

Aprea Therapeutics appoints Kennedy as Chief Medical Advisor

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Feb 4, 2026, 8:30 AM EST - 7 months ago

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

2026-01-29T17:30:16.000Z - 7 months ago

Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

Aprea Therapeutics prices 6.29M shares at 89c in private placement

2026-01-29T13:37:09.000Z - 7 months ago

Aprea Therapeutics prices 6.29M shares at 89c in private placement

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

2026-01-29T13:36:47.000Z - 7 months ago

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Jan 29, 2026, 8:27 AM EST - 7 months ago

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 29, 2026, 8:25 AM EST - 7 months ago

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aprea Therapeutics files to sell 5.5M shares of common stock for holders

2025-12-19T21:20:46.000Z - 8 months ago

Aprea Therapeutics files to sell 5.5M shares of common stock for holders

Aprea Therapeutics Registration statement: Registration Filing

Dec 19, 2025, 7:00 AM EST - 8 months ago

Aprea Therapeutics Registration statement: Registration Filing

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

Dec 18, 2025, 8:30 AM EST - 8 months ago

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2025, 8:30 AM EST - 9 months ago

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Nov 12, 2025, 8:30 AM EST - 10 months ago

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Aprea Therapeutics Earnings release: Q3 2025

Aprea Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Aprea Therapeutics Quarterly report: Q3 2025

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Oct 24, 2025, 8:30 AM EDT - 10 months ago

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Oct 15, 2025, 8:00 AM EDT - 11 months ago

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Aprea Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 3:30 PM EDT - 1 year ago

Aprea Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Quarterly report: Q2 2025

Aprea Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Earnings release: Q2 2025

Aprea Therapeutics Slides: Corporate Presentation

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Slides: Corporate Presentation

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Jun 25, 2025, 9:00 AM EDT - 1 year ago

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

May 14, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Quarterly report: Q1 2025

Aprea Therapeutics Earnings release: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Earnings release: Q1 2025

Aprea Therapeutics Slides: Corporate Presentation

May 14, 2025, 4:00 AM EDT - 1 year ago

Aprea Therapeutics Slides: Corporate Presentation

Aprea Therapeutics Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Proxy statement: Proxy Filing

Aprea Therapeutics Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Proxy statement: Proxy Filing

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Aprea Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Earnings release: Q4 2024

Aprea Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Annual report: Q4 2024

Aprea Therapeutics Slides: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Slides: Q4 2024

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Feb 5, 2025, 8:00 AM EST - 1 year ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Dec 11, 2024, 8:30 AM EST - 1 year ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Aprea Therapeutics Slides: Corporate Presentation

Nov 7, 2024, 11:00 AM EST - 1 year ago

Aprea Therapeutics Slides: Corporate Presentation

Aprea Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Aprea Therapeutics Quarterly report: Q3 2024

Aprea Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Aprea Therapeutics Earnings release: Q3 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 5:15 PM EDT - 2 years ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 2 years ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aprea Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Quarterly report: Q2 2024

Aprea Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Earnings release: Q2 2024

Aprea Therapeutics Transcript: Study Update

Jun 24, 2024, 9:00 AM EDT - 2 years ago

Aprea Therapeutics Transcript: Study Update

Aprea Therapeutics Slides: Study Update

Jun 24, 2024, 9:00 AM EDT - 2 years ago

Aprea Therapeutics Slides: Study Update

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Jun 17, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 28, 2024, 8:45 AM EDT - 2 years ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 14, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

Aprea Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Quarterly report: Q1 2024

Aprea Therapeutics Earnings release: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Earnings release: Q1 2024

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 13, 2024, 4:01 PM EDT - 2 years ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

May 2, 2024, 9:15 AM EDT - 2 years ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Aprea Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Proxy statement: Proxy Filing

Aprea Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Proxy statement: Proxy Filing

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Apr 10, 2024, 12:00 PM EDT - 2 years ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics Registration statement: Registration Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Registration statement: Registration Filing

Aprea Therapeutics Annual report: Q4 2023

Mar 26, 2024, 9:00 AM EDT - 2 years ago

Aprea Therapeutics Annual report: Q4 2023

Aprea Therapeutics Earnings release: Q4 2023

Mar 26, 2024, 9:00 AM EDT - 2 years ago

Aprea Therapeutics Earnings release: Q4 2023

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 26, 2024, 7:45 AM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 14, 2024, 7:48 AM EDT - 2 years ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 11, 2024, 8:29 AM EDT - 2 years ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Netonay
Netonay Sep. 10 at 5:34 PM
$APRE Some day I’m going to wake up and this shit is going to be 25 plus ,,, then people will chase! Mark this post !
0 · Reply
MavrickPete
MavrickPete Sep. 8 at 1:31 AM
$APRE $41.3M cash as of June 2026, with runway into Q1 2028..!!
0 · Reply
Tradingistheway
Tradingistheway Sep. 7 at 4:49 AM
$APRE https://www.instagram.com/reel/DcbM1l5iJBX/?stkn=MTBsNXkycDVmMmY2aw==
0 · Reply
focafoca99
focafoca99 Aug. 28 at 12:30 PM
$APRE expanded its patent portfolio for precision oncology programs, adding new WEE1 and ATR filings.
0 · Reply
Olyaboo
Olyaboo Aug. 27 at 2:30 PM
$APRE Im holding
0 · Reply
Arttard
Arttard Aug. 27 at 2:25 PM
$APRE why Down Today?
0 · Reply
CoachHendo
CoachHendo Aug. 27 at 8:18 AM
$APRE $NVTS $GNPX Lotto Plays!
0 · Reply
Dcvcool
Dcvcool Aug. 27 at 2:16 AM
$APRE wow not the greatest management and no real trial results yet A real lotto ticket I don’t play the lottery though
0 · Reply
Heroforest
Heroforest Aug. 26 at 5:13 PM
$APRE new here anyone what’s the near term catalyst? In q4 2026 and 2027? Thanks
1 · Reply
PennySearch
PennySearch Aug. 26 at 3:33 PM
📈 Top Penny Stock Movers by Relative Volume $APRE — 6.73x RVOL Move: +10% Volume: 1.8M (274.7K average) Market Cap: $13.2M Day Range: 0.96 – 1.16 52-Week Range: 0.55 – 1.69 $XPON — 5.79x RVOL Move: +69% Volume: 27.6M (4.8M average) Market Cap: $8.5M Day Range: 6.30 – 11.79 52-Week Range: 2.77 – 24.60 $DAIC — 3.26x RVOL Move: +31% Volume: 33.7M (10.3M average) Market Cap: $6.2M Day Range: 4.61 – 6.69 52-Week Range: 0.37 – 111.97 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.
0 · Reply
Olyaboo
Olyaboo Aug. 26 at 2:46 PM
$APRE Strong Clinical Progress… Q4…. 💥
0 · Reply
johnnyutah007
johnnyutah007 Aug. 26 at 1:47 PM
$APRE 🔥
0 · Reply
CaptainDeadpool
CaptainDeadpool Aug. 26 at 1:43 PM
$APRE opinions on if this will continue?
1 · Reply
ranyc71
ranyc71 Aug. 26 at 1:35 PM
$APRE 👀👀 LFG. $CRE $DAIC
0 · Reply
Wolfie_Runs_Alone
Wolfie_Runs_Alone Aug. 26 at 1:05 PM
$APRE Funds appear to be soaking up this 10millie float pharma play. Markets anticipating the details of their two recent patient successes. 👀💪🏽🙏
0 · Reply
MrPaperPaperz
MrPaperPaperz Aug. 26 at 5:54 AM
$APRE holding above here for compliance so no rs needed?
0 · Reply
Olyaboo
Olyaboo Aug. 26 at 4:38 AM
$APRE
0 · Reply
Wolfie_Runs_Alone
Wolfie_Runs_Alone Aug. 25 at 6:16 PM
$APRE Beautiful, orderly trading. How refreshing!!
0 · Reply
SNOWBALLDB321
SNOWBALLDB321 Aug. 25 at 3:45 PM
$APRE Combining Aprea's APR-246 (eprenetapopt) with Apreas ATR and WEE1 inhibitors makes strong biological sense because they all target the DNA damage response and cell cycle checkpoints, creating a powerful "synthetic lethality" approach for cancers with TP53 mutations or replication stress. ATR Kinase: Detects single-stranded DNA and replication stress during the S-phase (DNA replication). It pauses the cell cycle to let the cell fix damaged DNA. WEE1 Kinase: Controls the G2/M checkpoint. It prevents cells with damaged DNA from entering premature mitosis. ATR and WEE1 Inhibiting together forces cancer cells with broken DNA to rush into mitosis. This causes mitotic catastrophe and cell death. APR-246 reactivates mutant TP53 proteins back to a normal, tumor-suppressing shape and increases oxidative stress inside cancer cells. Normal cells use the p53-controlled G1 checkpoint, but TP53-mutant cancer cells rely entirely on ATR and WEE1 for survival.
1 · Reply
like11
like11 Aug. 25 at 3:25 PM
$APRE easy 200%
0 · Reply
Wolfie_Runs_Alone
Wolfie_Runs_Alone Aug. 25 at 2:45 PM
$APRE Look at the weekly volume and price appreciation compared to daily averages. Then think $MRNA . 🤔😉🙏💪🏽 They'll be reportingnout on details of their recent successes soon.
0 · Reply
johnnyutah007
johnnyutah007 Aug. 25 at 2:32 PM
$APRE 🔥
0 · Reply